TABLE 1 Finnish Otitis Media Vaccine Trial: Causes of AOM Episodes and Impact of PCV 7 Immunization on Incidence PCV-7
CONTROL DIFFERENCE CAUSE EPISODES EPISODES (%) Culture-confirmed pneumococcus 271 414 34 Pneumococcal serotype in vaccine 107 250 57 Vaccine cross-reactive serotypes * 41 84 51 Other pneumococcal serotypes 125 95 33 Haemophilus influenzae 315 287 11 Moraxella catarrhalis 379 381 1 * 6A, 9N, 1813, 19A, 23A.
To compare the immunogenic impact of coadministration of the PCV-7
and Hib vaccines with the combined DTaP-HepB-IPV vaccine to that achieved via separate administration of all component vaccines, the investigators enrolled a total of 575 healthy infants from 22 U.S.
No decline in pneumococcal meningitis occurred in older people, as has been seen with other types of invasive pneumococcal disease after the introduction of PCV-7
, he said at the annual meeting of the Infectious Diseases Society of America.
was introduced in April 2009, followed by RV in August of the same year.
influenzae carriage after vaccination with PCV-7
(7,8), we questioned whether the effects of PCV-7
could be even more extensive than initially believed.
program began in April 2003 when a four-dose schedule (at 2, 4 and 6 months with a booster at 18 months) was offered to medically high-risk and Aboriginal children aged 2 to 59 months.
However, they were unsure of a definite link between the vaccine and the emergence of 19A strains because those strains have also increased in some countries without the PCV-7
In the present study, the theoretical estimated coverage by the heptavalent conjugated vaccine (PCV-7
; serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) was 68.6% in children less than 6 years of age; 75.6% with the 10-valent conjugated vaccine (PCV-10; serotypes contained in PCV-7
, plus serotypes 1, 5, and 7F); and 86.0% with the 13-valent conjugated vaccine (PCV-13; serotypes contained in PCV-10, plus serotypes 3, 6A, and 19A).
covers 70% of invasive isolates and is therefore a worthwhile vaccine to roll out, PCV-10 would increase coverage to up to 85%.
By reviewing immunization records, we confirmed that all had completed the PCV-7
series before becoming ill.
The three groups achieved similar rates of seroprotection for HepB and Hib, and seropositivity for PCV-7
was high in all groups.